吉非替尼联合培美曲塞二钠和顺铂治疗晚期肺腺癌的疗效分析

打开文本图片集

摘 要 目的：观察吉非替尼联合培美曲塞二钠和顺铂对晚期肺腺癌的临床疗效。方法：将98例晚期肺腺癌患者随机分为对照组和研究组，各49例。对照组给予培美曲塞二钠+顺铂方案进行治疗，研究组在对照组基础上加用吉非替尼治疗，对比两组临床疗效、肿瘤标志物水平和不良反应。结果：研究组治疗总有效率高于对照组；两组的肿瘤标志物水平均低于治疗前，且研究组低于对照组；研究组不良反应发生率低于对照组（P

关键词 吉非替尼 培美曲塞二钠 顺铂 晚期肺腺癌

中图分类号：R979.19； R734.2 文献标志码：A 文章编号：1006-1533（2023）05-0019-02

引用本文 陈辉， 崔明良， 黄武君. 吉非替尼联合培美曲塞二钠和顺铂治疗晚期肺腺癌的疗效分析[J]. 上海医药， 2023， 44（5）： 19-20； 29.

Efficacy of gefitinib combined with pemetrexed disodium and cisplatin in the treatment of advanced lung adenocarcinoma

CHEN Hui， CUI Mingliang， HUANG Wujun

（Department of Oncology， Balihu General Hospital of the First People’s Hospital of Jiujiang City， Jiujiang 332000， China）

ABSTRACT Objective： To investigate the clinical efficacy of gefitinib combined with pemetrexed disodium and cisplatin in the treatment of advanced lung adenocarcinoma. Methods： Ninety-eight patients with advanced lung adenocarcinoma were randomly divided into a control group and a study group， with 49 cases each. The control group was treated with pemetrexed disodium combined with cisplatin， while the study group was treated with gefitinib besides pemetrexed disodium combined with cisplatin. Clinical efficacy， levels of tumor markers and incidence of adverse events were compared between the two groups. Results： The overall clinical efficacy was higher in the study group than the control group. The levels of tumor markers in both groups were lower after treatment than before and moreover in the study group than the control group. The incidence of adverse events was lower in the study group than the control group （P

KEY WORDS gefitinib； pemetrexed disodium； cisplatin； advanced lung adenocarcinoma

肺腺癌属于非小细胞肺癌的一种，发病率占非小细胞肺癌的50%左右，其早期临床特征不明显，很多患者一旦确诊往往已是晚期[1]。（剩余3628字）